pirinixic acid has been researched along with Obesity in 17 studies
pirinixic acid: structure
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "Lack of leptin (ob) protein causes obesity in mice." | 3.69 | Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. ( Kallen, CB; Lazar, MA, 1996) |
| "PPAR-alpha activation reduced BM and treated insulin resistance (IR) and NAFLD by increasing the number of mitochondria and reducing hepatic gluconeogenesis and de novo lipogenesis protein and gene expressions in a murine obesity model." | 1.46 | Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice. ( Barreto, AB; Graus-Nunes, F; Mandarim-de-Lacerda, CA; Rachid, TL; Souza-Mello, V; Veiga, FMS, 2017) |
| "Moreover, Wy-14,643 treatment reduced inflammation and the expression of macrophage-specific genes in white adipose tissue (WAT)." | 1.33 | Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. ( Hada, Y; Ito, Y; Kadowaki, T; Maki, T; Takekawa, S; Tsuchida, A; Yamauchi, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Bhattacharjee, J | 1 |
| Borra, VJ | 1 |
| Salem, ESB | 1 |
| Zhang, C | 1 |
| Murakami, K | 2 |
| Gill, RK | 1 |
| Kim, A | 1 |
| Kim, JK | 1 |
| Salazar-Gonzalez, RM | 1 |
| Warren, M | 1 |
| Kohli, R | 1 |
| Nakamura, T | 1 |
| Veiga, FMS | 1 |
| Graus-Nunes, F | 1 |
| Rachid, TL | 1 |
| Barreto, AB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Souza-Mello, V | 1 |
| Oberkofler, H | 1 |
| Pfeifenberger, A | 1 |
| Soyal, S | 1 |
| Felder, T | 1 |
| Hahne, P | 1 |
| Miller, K | 1 |
| Krempler, F | 1 |
| Patsch, W | 1 |
| Chen, R | 1 |
| Liang, F | 1 |
| Morimoto, S | 1 |
| Li, Q | 1 |
| Moriya, J | 1 |
| Yamakawa, J | 1 |
| Takahashi, T | 1 |
| Iwai, K | 1 |
| Kanda, T | 1 |
| Funai, K | 1 |
| Song, H | 1 |
| Yin, L | 1 |
| Lodhi, IJ | 1 |
| Wei, X | 1 |
| Yoshino, J | 1 |
| Coleman, T | 1 |
| Semenkovich, CF | 1 |
| Edvardsson, U | 2 |
| von Löwenhielm, HB | 1 |
| Panfilov, O | 1 |
| Nyström, AC | 1 |
| Nilsson, F | 1 |
| Dahllöf, B | 2 |
| Ide, T | 1 |
| Tsunoda, M | 1 |
| Mochizuki, T | 1 |
| Fu, J | 1 |
| Oveisi, F | 1 |
| Gaetani, S | 1 |
| Lin, E | 1 |
| Piomelli, D | 1 |
| Tsuchida, A | 1 |
| Yamauchi, T | 1 |
| Takekawa, S | 1 |
| Hada, Y | 1 |
| Ito, Y | 1 |
| Maki, T | 1 |
| Kadowaki, T | 1 |
| Li, PP | 1 |
| Shan, S | 1 |
| Chen, YT | 1 |
| Ning, ZQ | 1 |
| Sun, SJ | 1 |
| Liu, Q | 1 |
| Lu, XP | 1 |
| Xie, MZ | 1 |
| Shen, ZF | 1 |
| Wang, Y | 1 |
| Botolin, D | 1 |
| Xu, J | 1 |
| Christian, B | 1 |
| Mitchell, E | 1 |
| Jayaprakasam, B | 1 |
| Nair, MG | 1 |
| Nair, M | 1 |
| Peters, JM | 3 |
| Busik, JV | 1 |
| Busik, J | 1 |
| Olson, LK | 1 |
| Jump, DB | 1 |
| Toyoda, T | 1 |
| Kamei, Y | 1 |
| Kato, H | 1 |
| Sugita, S | 1 |
| Takeya, M | 1 |
| Suganami, T | 1 |
| Ogawa, Y | 1 |
| Kallen, CB | 1 |
| Lazar, MA | 1 |
| Poynter, ME | 1 |
| Daynes, RA | 1 |
| Bergström, M | 1 |
| Alexandersson, M | 1 |
| Bamberg, K | 1 |
| Ljung, B | 1 |
| Akiyama, TE | 1 |
| Nicol, CJ | 1 |
| Fievet, C | 1 |
| Staels, B | 1 |
| Ward, JM | 1 |
| Auwerx, J | 1 |
| Lee, SS | 1 |
| Gonzalez, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome[NCT02122666] | 100 participants (Anticipated) | Observational | 2014-03-31 | Active, not recruiting | |||
| Full-fat Yogurt and Glucose Tolerance[NCT03577119] | 13 participants (Actual) | Interventional | 2018-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pirinixic acid and Obesity
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
16 other studies available for pirinixic acid and Obesity
| Article | Year |
|---|---|
Hepatic Ago2 Regulates PPARα for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery.
Topics: Animals; Argonaute Proteins; Bariatric Surgery; Glucose; Glucose Tolerance Test; Glycemic Control; H | 2021 |
Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.
Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Dietary Fats; fas Receptor; Ge | 2017 |
Aberrant hepatic TRIB3 gene expression in insulin-resistant obese humans.
Topics: Carrier Proteins; Cell Cycle Proteins; Gene Expression; Heat-Shock Proteins; Hep G2 Cells; Humans; I | 2010 |
The effects of a PPARalpha agonist on myocardial damage in obese diabetic mice with heart failure.
Topics: Adiponectin; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Heart Failure; Mice | 2010 |
Muscle lipogenesis balances insulin sensitivity and strength through calcium signaling.
Topics: Adenylate Kinase; Animals; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Ce | 2013 |
Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators.
Topics: Amino Acids; Animals; Carbohydrate Metabolism; Diabetes Mellitus; Electrophoresis, Gel, Two-Dimensio | 2003 |
Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
Topics: Animals; Biomarkers; Gene Expression Regulation; Insulin; Insulin Receptor Substrate Proteins; Lipid | 2004 |
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Topics: Animals; Body Weight; Butyrates; CD36 Antigens; Cholesterol; Coenzyme A Ligases; Eating; Endocannabi | 2005 |
Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Topics: Animals; Blood Glucose; Epididymis; Glucose Tolerance Test; Hypoglycemic Agents; Inflammation; Insul | 2005 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity.
Topics: Acetyltransferases; Adult; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Dia | 2006 |
Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Inflammatory Agents; Cell Communication; Cell Line; Chemokin | 2008 |
Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Gene Expression Regulation; Hypoglycemic Agents; Lept | 1996 |
Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging.
Topics: Acyl-CoA Oxidase; Aging; Animals; Base Sequence; Catalase; Cytokines; Dehydroepiandrosterone Sulfate | 1998 |
Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
Topics: Animals; Electrophoresis, Gel, Two-Dimensional; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; | 1999 |
Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines.
Topics: Animals; Body Weight; Cholesterol; Female; Lipid Metabolism; Liver; Male; Mice; Mice, Congenic; Mice | 2001 |